Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
August 2019
-
Living with HFpEF – a patient’s story
Cynthia lives with Heart Failure with preserved Ejection Fraction, a complex and challenging condition.
-
Key ReleaseNovartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studiesIn ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate over Aubagio®* (teriflunomide) in patients with relapsing forms of MS (RMS)[1] Key secondary…
-
Featured NewsBlood Cancer Awareness Month - Cutting Edge Innovation in Hematology
Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
-
Featured NewsImpact Measurement and Valuation
Novartis joins seven global companies to found the Value Balancing Alliance
-
Media ReleaseNovartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019PARAGON-HF trial will provide Entresto® (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)[1] New PROVE-HF and EVALUATE-HF studies will…
-
Flexibility at Novartis: Shamsah Kazani
Kazani describes how her flexible work arrangement helps her balance her personal and professional lives.
-
Media ReleaseAveXis Statement on Changes to Senior Leadership TeamAveXis announces Page Bouchard, DVM has been appointed Senior Vice President of Research and Chief Scientific Officer, effective August 5, 2019. Dr. Bouchard is a 27-year industry veteran with…
-
Media ReleaseSandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent caseSandoz to appeal court ruling to United States Court of Appeals for the Federal Circuit Ruling prevents launch of important, affordable treatment option for US patients affected by chronic…
-
Using Super-Resolution Microscopy To See Neurodegeneration
Novartis data scientists are using super-resolution microscopy to see neurodegeneration the moment it starts.
-
Media ReleaseNovartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophyBasel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and…
-
Keeping the heart of patients at the heart of everything we do
For over 60 years Novartis has been committed to helping people with cardiovascular disease and we remain steadfast in that commitment to this day.
Pagination
- ‹ Previous page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- …
- 152
- › Next page